Biodesix (BDSX) Stock Fair Value Moves Lower After Q3 Miss And Guidance Cut
Biodesix, Inc. (BDSX) Presents at 2026 UBS Global Healthcare Conference Transcript
HC Wainwright & Co. Maintains Buy on Biodesix, Lowers Price Target to $34
Lake Street Maintains Buy on Biodesix, Lowers Price Target to $30
Biodesix (BDSX) Q3 2026 Earnings Call Transcript
Biodesix Inc (BDSX) (Q3 2026) Earnings Call Highlights: Revenue Growth Offset by Sales Force ...
Biodesix Stock Crashes Nearly 30% After Q3 Revenue Miss, Slashes 2026 Outlook
Biodesix, Inc. (BDSX) Q3 2026 Earnings Call Transcript
What Biodesix (BDSX) Said on Its Q3 Earnings Call
Biodesix, Inc. (BDSX) Reports Q3 Loss, Lags Revenue Estimates
Biodesix Announces Third Quarter 2026 Results and Highlights
Biodesix Q3 2026 Earnings Call Transcript
Biodesix Lowers FY2026 Sales Guidance from $108.000M-$114.000M to $101.000M-$103.000M vs $111.817M Est
Biodesix to Participate in Upcoming Investor Conferences
All You Need to Know About Biodesix (BDSX) Rating Upgrade to Buy
Biodesix to Report Third Quarter 2026 Financial Results on November 5, 2026
American College of Chest Physicians Publishes New Framework for Lung Nodule Programs Recommending Biomarkers for Risk Stratification
Biodesix Adds Digital Diagnostics to Lung Pipeline, Creating New Growth Platform Combining Blood and Imaging Biomarkers
Biodesix Adds AI-Powered Imaging Test To Expand Lung Cancer Risk Screening
Biodesix (BDSX) Stock Sees Fair Value Lift As Analysts Back MRD Growth
Sign up for free to unlock this feature.
Creating your account...
Your account has been created. Redirecting...
Loading...
This feature requires a premium subscription to unlock unlimited historical data and advanced analysis tools.